{"disease":{"id":"chromophobe-renal-cell-carcinoma","name":"chromophobe renal cell carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04623502","title":"An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy","phase":"NA","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":false},{"nct_id":"NCT06339138","title":"Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":589,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03866382","title":"Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":314,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07243067","title":"Tumor-Derived Extracellular Vesicles for Noninvasive Molecular Classification of Kidney Cancer","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04071223","title":"Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":134,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03177239","title":"Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":85,"lead_sponsor_name":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group","has_results":false},{"nct_id":"NCT06805825","title":"A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":67,"lead_sponsor_name":"Novelty Nobility, Inc.","has_results":false},{"nct_id":"NCT04413123","title":"Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Bradley A. McGregor, MD","has_results":false},{"nct_id":"NCT01767636","title":"Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"Mayo Clinic","has_results":true},{"nct_id":"NCT03685448","title":"ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group","has_results":false},{"nct_id":"NCT03541902","title":"Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":32,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06318871","title":"Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false}],"total":12},"guidelines":[],"source":"Drug Landscape verified database"}